We have moved offices.

Our new address is:

1450 Broadway, 24th Floor, New York, NY 10018.

Our phone number (212-582-0900) and fax number (212-582-9563) remain the same.

Harris & Harris Group, Inc.^®, is a publicly traded venture capital firm exclusively focused on investing in companies enabled by nanotechnology and microsystems. Nanotechnology is measured in nanometers, which are units of measurement in billionths of a meter. Microsystems are measured in micrometers, which are units of measurement in millionths of a meter. We often use "tiny technology," to describe both of these disciplines. Most of our portfolio companies use nanoscale-enabling technologies.

With over 30 nanotechnology companies in our portfolio, Harris & Harris Group, Inc., is one of the most active nanotechnology investors in the world. We have funded companies developing nanoscale-enabled solutions in solid state lighting, emerging memory devices, printable electronics, photovoltaics, battery technologies, thermal and power management, next-generation semiconductor devices and equipment, quantum computing, as well as in various life-science applications of nano-structured materials.

We consider a company to fit our investment thesis if the company employs, intends to employ or enables technology that we consider to be at the microscale, nanoscale or smaller and if the employment of that technology is material to its business plan. We are interested in funding entrepreneurs with energy, vision and the desire to build great companies.

We are a traditional, early-stage venture capital firm except in capital structure and focus. We participate in venture capital syndicates in most of our investments, alongside top-tier venture capital firms as well as strategic (corporate) investors. Harris & Harris Group will act as a lead investor. As a publicly held company that invests only its own, permanent capital, we are able to be an unusually patient investor. Because we invest only in nanotechnology and microsystems, we have specialized expertise and a unique ecosystem of portfolio companies and other relationships.

Portfolio Company Highilght:

METABOLON, INC.

Metabolon, Inc., uses a proprietary technology platform in metabolomics to map changes in metabolic pathways. Measurement of the spectrum of cellular biochemical changes and the subsequent mapping of these changes to metabolic pathways permits a direct understanding of a disease. This information is used for the discovery and development of drugs, the identification of biomarkers and the early diagnosis of disease states.
www.metabolon.com